Catalyst Oncology is a niche oncology clinical research organization (CRO) devoting time, energy, and capital to supporting biotechs in bringing next-generation hematologic oncology (heme/onc) therapies to cancer patients in need. Clinical trials in hematologic malignancies are complex, more so than in solid tumors and thus require a higher level of expertise in your CRO partner. Bringing effective heme/onc therapies to proof-of-concept and then to market as fast as possible is our mission because every second counts for patients and their families living with blood cancer.
Active portfolio in a range of hematologic oncology trials
- Leukemias
- AML, CLL/SLL, CML
- Lymphomas
- DLBCL, FL, MCL, NHL, PTCL
- Multiple Myeloma (MM)
- Myelodysplastic Syndrome (MDS)
- Rare Indications
- AITL, PTCL, MZL
We understand the nuances of hematologic oncology trials
- Complex endpoints
- (Cheson, Lugano, IMWG etc.)
- Patients with significant comorbidities
- I/E criteria, wash-out windows, rescue medications
- Competitive clinical trial landscape
- Challenging enrollment rates
Active next-generation oncology experience
Working largely in early- to mid-phase development across a range of both solid and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.
